Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...

Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...

Novo Nordisk India and Emcure Pharma have partnered to launch Poviztra (semaglutide 2.4 mg), a second brand of Wegovy®, in ...

GLP-1 injections are medications that mimic the natural hormone that controls blood sugar and creates the feeling of fullness ...

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

After a few months on fat jabs such as Wegovy or Mounjaro, the feeling of suppression can start to wane and weight loss can ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...

Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...